問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

Division of Dermatology

Taipei Chang Gung Medical Foundation (在職)

Division of Dermatology

Chiayi Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Dermatology

更新時間:2023-09-19

紀景琪
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

31Cases

2024-02-01 - 2026-07-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-11-01 - 2028-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-04-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2024-09-15 - 2026-12-31

Phase III

Active
Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of unknown origin (CPUO)
  • Condition/Disease

    chronic pruritus of unknown origin (CPUO)

  • Test Drug

    injection

Participate Sites
4Sites

Recruiting4Sites

2023-04-01 - 2028-12-31

Phase II

Active
An Open-Label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate to severe atopic dermatitis
  • Condition/Disease

    moderate to severe atopic dermatitis

  • Test Drug

    injective

Participate Sites
7Sites

Recruiting7Sites

2025-06-15 - 2027-04-17

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-01-09 - 2026-02-28

Phase III

Completed
A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
  • Condition/Disease

    Alopecia Areata

  • Test Drug

    PF-06651600

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2026-12-31

Phase III

Active
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK 279 in Subjects With Moderate-to-Severe Plaque Psoriasis
  • Condition/Disease

    Moderate-to-Severe Plaque Psoriasis

  • Test Drug

    tablets

Participate Sites
8Sites

Recruiting8Sites

2021-11-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4